Skip to main content

Left Ventricular Ejection Fraction clinical trials at UCSF

1 research study open to eligible people

Left ventricular ejection fraction is a measure of how well the heart pumps blood with each beat. UCSF is conducting a trial to see if a drug called levosimendan can help people with certain heart problems exercise better. This study compares the effects of levosimendan to a placebo.

Showing trials for
  • LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

    open to eligible people ages 18-85

    This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

    San Francisco, California and other locations

Last updated: